Subscribe to Newsletter

Discovery & Development


Discovery & Development Drug Discovery

CRISPR With Caution

| Rob Coker | 3 min read

Deputy editor Rob Coker recalls his trip to the labs of Caszyme, Vilnius, where he spoke with CEO Monika Paule about the potential of genome editing

Discovery & Development Drug Discovery

Alzheimer’s Treatment Timeline

| Stephanie Sutton | 2 min read

With new drugs showing promise for Alzheimer’s, is the drug development drought over?

Discovery & Development Drug Discovery

Fabulously Interesting

| 6 min read

Sitting Down With… Sharon L Rogers, AmyriAD CEO, Renowned drug developer, 2023 Power Lister, and Olympic figure skating official

Discovery & Development Clinical Trials

Ignaz Semmelweis, We Salute You

| Rob Coker | 4 min read

In the second episode of the We Salute You series, we focus on much maligned Hungarian physician Ignaz Semmelweis

Discovery & Development Drug Discovery

Llamas Versus Dengue

| Stephanie Sutton | 3 min read

Why one company is focusing on camelid-derived antibodies to tackle dengue.

Discovery & Development Drug Discovery

Exploring Alzheimer’s in Women

| Jamie Irvine | 2 min read

Studying the link between Alzheimer’s risk, estrogen levels, and menopausal status in women

Discovery & Development Drug Discovery

FDA Approves First OTC Contraceptive

| Jamie Irvine | 2 min read

Perrigo’s Opill receives FDA approval following unanimous support from advisory committees

Discovery & Development Drug Delivery

The Realities of Herbal Remedies

| Jamie Irvine | 3 min read

How scientists extracted a treatment for episodic ataxia from traditional Kwakwaka'wakw medicine

Discovery & Development Drug Delivery

Casing the Joint

| Paul Rennie | 5 min read

We need non-opioid options for pain relief. Paradigm Biopharmaceuticals discuss their studies into a new option for osteoarthritis patients

Discovery & Development Drug Discovery

Honey, I Shrunk the Molecules

| Jamie Irvine | 2 min read

Researchers demonstrate that microRNA-132 can significantly affect different brain cells, with potential implications for Alzheimer’s disease.


Sister Publications

You might be interested in our Sister Publications:

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register